

Transparency notification Form TR-1 BE PART I

1) Status of the notification			
	Final	1	
2) Issuer			
	BIOCARTIS		
Identification number	r 0505-640-808		
3) Reason for the notification	1		
	Acquisition or disposal of the control of an undertaking	that holds a participating interest in an issuer	
	Passive crossing of a threshold		4
4) Notification by			
	A parent undertaking or a controlling person		4
	- Paraticular and Controlling Polices		
5) Persons subject to the no	tification requirement		
	Name	Address (for legal entities)	
	Debiopharm Innovation Fund S.A. (formerly		
	Debiopharm Diagnostics SA)	Rue du Levant 146, 1920 Martigny, Switzerland	
	Debiopharm Holding S.A.	Rue du Levant 146, 1920 Martigny, Switzerland	
	Thierry Mauvernay	Chamin du Broz Ruchilly 113, 1000 Lausanna 25	
		Chemin du Praz-Buchilly 113, 1000 Lausanne 25	4
6) Persons that dispose of v			+
6) Persons that dispose of ve	oting rights (only to be filled in if art. 7 of the Lav		1
6) Persons that dispose of v	oting rights (only to be filled in if art. 7 of the Law	v applies)	1
6) Persons that dispose of v			[+
6) Persons that dispose of v	oting rights (only to be filled in if art. 7 of the Law	v applies)	+
6) Persons that dispose of v	oting rights (only to be filled in if art. 7 of the Law	Address (for legal entities)	+
6) Persons that dispose of v	oting rights (only to be filled in if art. 7 of the Law	v applies) Address (for legal entities)	+
•	Name Please continue entering the information in part II persons referred to in Sections 5 and 6	Address (for legal entities)	+
6) Persons that dispose of votation of the dispose of the dispo	Name Please continue entering the information in part II persons referred to in Sections 5 and 6	Address (for legal entities)	+
•	Name Please continue entering the information in part II persons referred to in Sections 5 and 6	Address (for legal entities)	+
7) Date on which the thresho	Name Please continue entering the information in part II persons referred to in Sections 5 and 6 28.11.2017	Address (for legal entities) concerning the Part II	+
•	Name Please continue entering the information in part II persons referred to in Sections 5 and 6 28.11.2017	Address (for legal entities) concerning the Part II	4
7) Date on which the thresho	Name Please continue entering the information in part II persons referred to in Sections 5 and 6 28.11.2017	Address (for legal entities) concerning the Part II	+
7) Date on which the threshold 8) Threshold that is crossed	Name Please continue entering the information in part II persons referred to in Sections 5 and 6 28.11.2017 (in %)	Address (for legal entities) concerning the Part II	4
7) Date on which the threshold 8) Threshold that is crossed	Name Please continue entering the information in part II persons referred to in Sections 5 and 6 28.11.2017 (in %)	Address (for legal entities) concerning the Part II	+
7) Date on which the threshold 8) Threshold that is crossed	Name Please continue entering the information in part II persons referred to in Sections 5 and 6 28.11.2017 (in %)	Address (for legal entities) concerning the Part II	+
7) Date on which the threshold 8) Threshold that is crossed	Name Please continue entering the information in part II persons referred to in Sections 5 and 6 28.11.2017 (in %)	Address (for legal entities) concerning the Part II	4
7) Date on which the threshold 8) Threshold that is crossed	Name Please continue entering the information in part II persons referred to in Sections 5 and 6 old is crossed 28.11.2017 (in %)	Address (for legal entities) concerning the Part II	+
7) Date on which the threshold 8) Threshold that is crossed 9) Denominator	Name Please continue entering the information in part II persons referred to in Sections 5 and 6 Did is crossed 28.11.2017 (in %) 10 If the holding has fallen below the lowest threshold	Address (for legal entities) concerning the Part II (DD/MM/YYYY) I, you have the option of not entering any numbers in Section 10	4
7) Date on which the threshold 8) Threshold that is crossed 9) Denominator	Name Please continue entering the information in part II persons referred to in Sections 5 and 6 old is crossed 28.11.2017 (in %)	Address (for legal entities) concerning the Part II (DD/MM/YYYY) I, you have the option of not entering any numbers in Section 10	+

10) Notified details

A) Voting rights	Previous notification	After the transaction				
	# of voting rights	# of votin	ng rights	% of voting rights		
Holders of voting rights		Linked to securities	Not linked to the securities	Linked to securities	Not linked to the securities	
Debiopharm Innovation Fund SA (formerly Debiopharm Diagnostics SA)	4'749'707	4'249'707		8.32%		
Debiopharm Holding SA	0	0		0.00%		
Thierry Mauvernay	0	0		0.00%		
Subtotal	4'749'707	4'249'707		8.32%		
TOTA	L	4'249'707	0	8.32%	0.00%	

For groups, start with the ultimate controlling natural person or legal entity.

The totals, subtotals and % will be updated once you have clicked on <CALCULATE>.

B) Equivalent financial instruments	After the transaction							
Holders of equivalent financial instruments	Type of financial instrument	Expiration date	Exercise period or date	# of voting rights that may be acquired if the instrument is exercised	% of voting rights	Settlement		
							+	
	TOTAL			0	0.00%			
The totals will be updated once you have clicked on <calculate></calculate>								
	TOTAL (A & B)	# of voting rights	% of voting rights					
CALCU				4'249'707	8.32%			

11) Full chain of controlled undertakings through which the holding is effectively held, if applicable

Debiopharm Innovation Fund S.A Thierry Mauvernay	. (formerly Debiopharm Diagnostics S	SA) is controlled by Debiopharm Holding S.A., which is controlled by	

12) In case of proxy voting for only one GM

	 _		_	(DD/MM/YYYY)
Holder	will cease to hold / will hold again	0	voting rights as of	

13) Additional information

This transparency declaration is mad There was a transfer of controlling p		vernay to Thierry N	Mauvernay.			

Done at	Lausanne, Switzerland
On	20.12.2017 (DD/MM/YYYY)
Name & capacity	Debiopharm Innovation Fund S.A President , Delegate of the Board
	Debiopharm Holding S.A President, Delegate of the Board
	Thierry Mauvernay - President, Delegate of the Board Debiopharm Group

Signature	_	The	-/				
Signature			Ano	Time !		—	
Signature				-	pour		>